Cartesian Therapeutics
RNAC
96 hedge funds and large institutions have $103M invested in Cartesian Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 16 closing their positions.
135% more call options, than puts
Call options by funds: $603K | Put options by funds: $257K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more capital invested
Capital invested by funds: $79.7M → $103M (+$23.5M)
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
4% more funds holding
Funds holding: 92 → 96 (+4)
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
0.06% more ownership
Funds ownership: 1.33% → 1.39% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.49M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.93M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.59M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.32M |
| 5 |
Two Sigma Investments
New York
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$3.66M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.69M |
| 3 |
Morgan Stanley
New York
|
-$1.53M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.33M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.23M |
RNAC Hedge Fund Activity: Q3 2022 in Review
96 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2022, worth a combined $103M — up 29% from $79.7M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RNAC positions and 16 closed out — a net gain of 4 holders — while 27 added to existing stakes and 26 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.49M. The largest seller was Mangrove Partners, cutting an estimated $3.66M.
- 96 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2022, up from 92 in Q2 2022.
- Funds reported $103M of Cartesian Therapeutics stock for Q3 2022, up 29% quarter-over-quarter.
- 20 funds opened new Cartesian Therapeutics positions in Q3 2022 and 16 closed out, a net change of +4 holders.
- The largest Cartesian Therapeutics buyer in Q3 2022 was Millennium Management, an estimated $6.49M added.
- The largest Cartesian Therapeutics seller in Q3 2022 was Mangrove Partners, an estimated $3.66M sold.
Based on aggregated 13F filings for Q3 2022.